tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Dyadic International (DYAI) and SCYNEXIS (SCYX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNYResearch Report), Dyadic International (DYAIResearch Report) and SCYNEXIS (SCYXResearch Report).

Alnylam Pharma (ALNY)

In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Hold rating on Alnylam Pharma, with a price target of $154.00. The company’s shares closed last Thursday at $150.86.

According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -20.7% and a 20.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Sensei Biotherapeutics, and Sarepta Therapeutics.

Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $210.20, representing a 41.9% upside. In a report issued on January 28, Leerink Partners also maintained a Hold rating on the stock with a $109.00 price target.

See the top stocks recommended by analysts >>

Dyadic International (DYAI)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Dyadic International today and set a price target of $7.00. The company’s shares closed last Thursday at $3.92, close to its 52-week low of $3.15.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.2% and a 36.5% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Aridis Pharmaceuticals, and Citius Pharmaceuticals.

Currently, the analyst consensus on Dyadic International is a Moderate Buy with an average price target of $6.50.

SCYNEXIS (SCYX)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on SCYNEXIS today and set a price target of $20.00. The company’s shares closed last Thursday at $5.11, close to its 52-week low of $4.21.

According to TipRanks.com, Livnat is a 2-star analyst with an average return of 0.2% and a 41.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Zynerba Pharmaceuticals, and Tarsus Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SCYNEXIS with a $19.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed